A palatable, heat-stable, easy-to-administer pellets’ formulation of LPV/r has received tentative USFDA approval for use in infants and young children. However, there are few data on its effectiveness and safety in routine care. The LIVING study evaluates the effectiveness, safety, PK and acceptability of LPV/r pellets + ABC/3TC (or AZT/3TC) dispersible tablets, in HIV+ children unable to swallow tablets in Kenya and Uganda.
An open-label, single-arm, prospective, multi-centre, phase-3b implementation study. Inclusion criteria: ARV naïve, on liquid LPV/r-based or failing NNRTI based ART; Weight ≥3 and <25kg. ART dosing based on WHO weight bands. Children assessed at baseline, 1 month then 3-monthly. Effectiveness was defined as a composite of VL<1000copies/ml, no death and being on study drugs. AEs were graded using DAIDS tables. Stunting was defined as height-for-age <-2SD, wasting as weight for height <-2SD and immunodeficiency following WHO age-specified CD4% cut offs.
As of 31/07/17, 610 patients had been enrolled, of whom 378 and 223 had reached WK24 and WK48 respectively, with a cohort retention of 88.7% (5 deaths). Baseline and WK 48 VL available in 220 children (49% female; 11% ART naïve,84% switched from LPV/r and 5% from NVP based ART). At Baseline, median (IQR) age in months was 20 (8-41) in ARV naïve, 47 (32-66) in LPV/r exposed and 50 (41-67) in NVP exposed, while VL results: Median VL (log10 cp/ml) and % with VL<50, <400 and <1000 cp/ml were 5.4 (4.7-5.8), 3.5%, 9.5% and 11.3% respectively in naïve, 2.2 (1.6-3.9), 29.5%, 57.9% and 63.5% in LPV/r exposed and 4.7 (4.3-5.4), 5.3%, 10.6% and 10.6% in the NVP exposed. At WK48, VL parameters were 2.1 (1.3-3.8),43.5%, 65.2% and 70% respectively in naïve,1.6(1.3-2.1), 56%, 80.9% and 85.1% in LPV/r exposed and 1.5(1.3-2.5), 58.3%, 75% and 83.3% in the NVP exposed. At baseline, Immunodeficiency, wasting and stunting were present in 70%, 50% and 35% of naïve respectively, 33%, 17% and 7.8% of LPV/r and in 40%, 20% and 14.3% of NVP exposed, reaching 36.4%, 9% and 5% of naïve, 21.7%, 2% and 3% % of LPV/r exposed and 40%, 0%, and 14.3% of NVP exposed respectively at Wk48. 21 children had 67 AEs grade 3/4, 2 leading to treatment stoppage.
LPV/r pellets were well accepted with minimal safety concerns. Naïve, those failing NVP, as well as those switching from LPV/r liquid were well suppressed at week 48 and had recuperated immunologically and clinically.